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with selected chronic conditions, who were alive and had continuous fee-for-service 
enrollment through the observation period and were not enrolled in Medicare and 
had at least one inpatient encounter in the follow up period (N= 15,806). The depend-
ent variable, 30-day readmission was calculated in the follow-up year as those with 
an inpatient admission within 30-days from the discharge date of the first observed 
hospitalization. Multi-level logistic regressions that accounted for beneficiaries nested 
within counties was used to examine the factors associated with 30-day readmis-
sions. RESULTS: In this study population 16.7% had all-cause 30-day readmissions. 
Hispanics were less likely to have 30-day readmission as compared with Caucasians 
[AOR= 0.80, 95% CI 0.70,0.92]. Adults with asthma [AOR= 1.16, 95% CI 1.03,1.32], 
dementia [AOR= 1.44, 95% CI 1.10,1.87], and stroke [AOR= 1.38, 95% CI 1.07,1.78] were 
more likely to have 30-day readmission and those with cardiac arrhythmia [AOR 
= 0.82, 95% CI 0.68,0.99] and hypertension [AOR= 0.85, 95% CI 0.76,0.94] were less 
likely to have 30-day readmissions. Adults with greater lengths of stay during the 
index hospitalization were more likely to have 30-day readmissions [AOR = 1.03, 95% 
CI 1.03,1.04]. CONCLUSIONS: Patient-level factors were associated with the risk of 
30-day readmissions. Programs designed to reduce the risk of 30-day readmissions 
may need to focus on appropriate disease management.
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OBJECTIVES: (1) To determine the proportion of hospitals with and without imple-
mentation of electronic health records. (2) To examine characteristics of hospitals 
that report implementation of EHR partially or completely versus those hospitals 
that report no implementation. METHODS: The study is a retrospective cross-
sectional using the 2012 American Hospital Association Annual Survey database. 
The dependent variable was the implementation of EHR completely or partially, 
while hospital characteristics like staffing, organization structure, accredita-
tions, ownership, services and facilities provided formed independent variables. 
Descriptive frequencies was followed by multinomial logistic regression to deter-
mine variables independently associated with complete or partial implementation 
of EHR. RESULTS: 12.6% of hospitals reported no implementation of EHRs while 
43.9% and 43.5% of hospitals implemented EHRs partially and completely respec-
tively. Overall characteristics of hospitals with complete and partial implementation 
were similar. The multinomial regression model revealed that increase in number 
of licensed beds, type of service being children’s general medical and surgical and 
heart was associated with complete implementation of EHR. Inversely limited ser-
vice hospitals, hospitals participating in a network, psychiatric and rehabilitation 
service hospitals, government non-federal, nongovernment not-for-profit hospi-
tals showed less likelihood of complete implementation of EHR. CONCLUSIONS: 
Our findings suggest a possible disconnect between psychiatric and rehabilitation 
hospitals’ larger, for-profit hospitals and smaller, not-for-profit hospitals in EHR 
implementation. Policy initiatives need to particularly target these institutions to 
bridge this possible gap.
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OBJECTIVES: The objective of our study was to analyze the efficiency of the 
Hungarian outpatient care system between 2003 and 2013, and to define the tech-
nical (TE) and scale efficiency (SE) of them. METHODS: The analysis covered all the 
Hungarian outpatients care units (N= 539 in 2003, N= 514 in 2006, N= 475 in 2010, 
N= 494 in 2013). We used the Data Envelopment Analysis method for analysis, and 
chose the following variables: the weekly mean working hours of physicians and 
non-physicians (inputs), number of medical procedures, number of cases, number 
of the activity points and the reimbursement paid by the National Health Insurance 
Fund Administration (outputs).The outpatient units were classified into two groups: 
integrated with hospitals, or independent outpatient clinics. RESULTS: Technical 
efficiency of the integrated units was 51.6% in 2003, and it was continuously increas-
ing in the following years. Scale efficiency also improved after 2003 (started from 
38%, then +27.7% to 2006, decreased -0.8% to 2010, +8% to 2013). The independent 
units’ TE in 2003 started from 35.3%, the following years it changed with an aver-
age of +/- 1-2% only. SE in 2003 was 39.9%, with average increase of 5% in the fol-
lowing years. In this study we found an optimum capacity of 100-200 hours/week 
minimum, and 500-600 hours/week maximum limit for the integrated units, and 
60-100 hours/week minimum and 500 hours/week maximum for the independent 
units. CONCLUSIONS: Our study revealed that integrated outpatient units showed 
better efficiency rate than independent outpatient units. This analysis can give a 
starting point to the optimization of the Hungarian outpatient-care system. The 
efficiency scores can give guidelines to the analyzed units in order to become more 
efficient, but the system also needs a more detailed examination.
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the various shortcomings of such programs that were implemented before in order 
to prepare a good program that has taken into consideration all the factors that are 
necessary for the economic delivery of healthcare without excluding the quality 
oriented approach. It will also act as a model for private insurance firms or other 
organizations to adopt such a model in order to produce better outcomes at lower 
costs in the future. Therefore, if this model is revised and implemented properly 
it will be an economic solution to this problem of the unsustainable increase in 
healthcare costs of the U.S.
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OBJECTIVES: The availability of drugs in a market may affect patient care, health 
outcomes and costs. The objective of this study was to assess differences in the 
availability of human drugs marketed in the US and in Switzerland as of January 1, 
2015. METHODS: Information about all drugs approved in the US and Switzerland 
was derived from the Food and Drug Administration (FDA) and the Swiss Agency 
for Therapeutic Products (Swissmedic) respectively. The list of drugs reimbursed 
by the Swiss mandatory insurance was extracted from the Federal Office of 
Public Health. Drugs were classified according to the WHO anatomical therapeu-
tic chemical classification (ATC). Descriptive statistics and the chi-square test 
were performed. RESULTS: The FDA listed 2,491 different active ingredients and 
combinations (AICs) approved and marketed in the US, while the Swissmedic list 
contained 1,345 AICs. The US listed 138 orphan drug AICs of which 68.8% were 
listed by Swissmedic and 63.0% were included in the Swiss reimbursement list. 
Overall, 73% of the US AICs were listed by Swissmedic and 67% were reimbursed, 
while 29.8% AICs approved in Switzerland were not approved in the US. A statis-
tically significant (p < 0.05) higher percentage of non-orphan AICs marketed in 
the US than orphan AICs were listed by Swissmedic. ATC codes were available for 
94.8% of drugs approved by the FDA and 99.1% by Swissmedic. The nervous system 
was the ATC class with the highest proportion of US approved drugs marketed 
in Switzerland. CONCLUSIONS: Two-thirds of the AICs marketed in the US were 
marketed in the Swiss market. Orphan drugs have less presence in the Swiss than 
in the US market. Future research should compare the approval processes in both 
countries and evaluate the impact of the availability of drugs on patients’ outcomes 
and cost.
PHP51
evaluation oF audit scoring consistency in a comPreHensive 
Feedlot management system and correlation witH Feedyard 
PerFormance based on average daily gain and dry Feed conversion 
in 11 us Feedlots
Bouwer A.1, Walter S.2, Holland R.3
1Zoetis LLC, Florham Park, NJ, USA, 2PCC Feedlot Investment Services Inc., Hydro, OK, USA, 
3Zoetis, Florham Park, NJ, USA
OBJECTIVES: A comprehensive Feedlot Management System (FMS) was devel-
oped to optimize feedyard processes. The FMS consists of 43 Standard Operating 
Procedures. The objective of this study was to correlate consistent implementation 
of the FMS with better feeding performance based on Average Daily Gain and Dry 
Matter Conversion. METHODS: To evaluate the correlation of audit scoring consist-
ency to feeding performance, two databases were analyzed: audit scoring over a 
16 month interval which measures compliance with the FMS requirements, and 3 
years of feedlot closeout data. Audit scores from 1/2012-4/2013 were evaluated and 
a Consistency Index (CI) developed based on four criteria. Audits were converted 
to the CI, and an LSMeans calculated to rank 11 feedlots. For feedyard performance 
evaluation, a database of feedlot closeout records from 2011- 2013 was used, rep-
resenting 12,235,158 head and 97 feedlots. An index combining ADG and DmConv 
was developed utilizing a ratio of the FMS lot value to the average 3 year database 
value. To further account for variables outside control of management, a regression 
model was used with inputs from the database (86,772 lots). The model output was 
the Performance Index for each feedlot. The inputs were statistically significant 
at p< 0.001. R-squared = 0.443. The corresponding CI and Performance Index for 
each feedyard were analyzed using the Pearson correlation coefficient. RESULTS: 
The Feeding Performance Index and CI are highly correlated at 70%. The range of 
CI scores was larger in the lower scoring feedlots, indicating more variability. The 
aggregate LSMeans CI improved 20% over time. CONCLUSIONS: There are many fac-
tors that affect feeding performance in commercial beef cattle production, and this 
variability can result in unstable returns. In the study group of feedlots implement-
ing the FMS, consistency based on audit scoring was highly correlated to feeding 
performance. The study supports utilization of a comprehensive FMS, that optimizes 
processes and incorporates accountability.
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OBJECTIVES: Hospital readmissions, defined as 30-day post-discharge readmission, 
are used for assessing the performance of a healthcare system and are quality indica-
tors of patient care. This study examined the relationship between readmissions and 
patient- and county-level variables using multi-level analyses. METHODS: A retro-
spective cohort approach with a baseline and a follow-up period was used. Patient-
level data were derived from multi-state Medicaid claims for the period between 2006 
and 2008. County-level variables were derived from the Area Health Resource File of 
2007. The study cohort consisted of non-elderly (21-64 years) Medicaid beneficiaries 
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OBJECTIVES: Payers in the U.S. are increasingly employing aggressive cost sharing 
strategies for specialty drugs. We conducted a systematic review of the published 
evidence on the associations between patient cost sharing and use of specialty drugs, 
use of non-drug medical services, and health outcomes and spending. METHODS: A 
MEDLINE search for U.S.-based studies published in English between 1995 and 2013 
was conducted using various combinations of terms for cost sharing and specialty 
drugs and/or common conditions for which they are indicated. Additional studies 
were obtained from reference lists of identified studies. Key methodological elements 
of the included studies were extracted and findings were captured to determine 
effects of cost sharing. RESULTS: We identified 15 articles that focused on one or more 
diseases, including MUltiple Sclerosis (n= 8), cancer (n= 7), Rheumatoid Arthritis (n= 5), 
and other conditions (n= 4). Majority of the studies (n= 14) used administrative claims 
data on privately insured patients from the year 2009 or earlier, during which time few 
private insurers were employing aggressive cost sharing for specialty drugs. Outcomes 
included prescription abandonment (n= 2), initiation or any utilization (n= 7), adher-
ence (n= 8), persistence/discontinuation (n= 6), number of claims (n= 1), and drug 
spending (n= 1). Findings generally indicated reductions in specialty drug utilization 
associated with higher cost sharing. However, the evidence was not consistent; the 
magnitude and/or statistical significance of the effects of cost sharing varied by dis-
ease and type of outcome. None of the studies examined the effect of specialty tier 
cost sharing seen under Medicare Part D or health insurance exchanges; or the effect 
of cost sharing on medical utilization, spending, or health outcomes. CONCLUSIONS: 
Evidence till date generally indicates reductions in specialty drug utilization associ-
ated with higher cost sharing, with effects varying by type of disease and specialty 
drug outcome. We draw upon our findings and the gaps in evidence to summarize 
future directions for research and policy.
PHP59
wHen is HealtH economics and outcomes researcH evidence 
imPortant to u.s. Payers?
Bajaj P.S.1, Willke R.J.2, Basu A.1, Sullivan S.D.1, Garrison L.P.1
1University of Washington, Seattle, WA, USA, 2Pfizer, Inc., New York, NY, USA
OBJECTIVES: The impact of health economics and outcomes research (HEOR) 
evidence on reimbursement decisions in the U.S. is not well understood, yet the 
continued and increasing investment in HEOR by pharmaceutical companies indi-
cates a perceived positive impact. We sought to understand U.S. payers’ prefer-
ences for HEOR evidence when making reimbursement decisions and to assess 
the alignment between payers and pharmaceutical companies with respect to the 
types of HEOR evidence that are important for various product and market sce-
narios. METHODS: We conducted an online, stated choice survey with individuals 
involved in the formulary decision-making process for U.S. payer and pharmacy 
benefit manager (PBM) organizations and those involved in the decision to invest 
in HEOR for pharmaceutical companies. We presented each individual with thirteen 
product profiles and asked them to rate the importance of several types of HEOR 
evidence to support U.S. formulary placement decisions for each profile. We used 
a logistic regression model to assess the product and market attributes that are 
associated with the stated importance of each type of evidence and to compare 
the alignment between respondents from pharmaceutical and payer/PBM organi-
zations. RESULTS: We received 31 responses from payers and 63 responses from 
individuals within pharmaceutical companies. Preliminary results indicate differ-
ences between the two stakeholder groups in the perceived importance of budget 
impact, resource utilization/cost offset, and adherence/compliance evidence. We 
report the most influential factors in the types of HEOR evidence that are stated 
to have an impact on formulary decision-making. CONCLUSIONS: The findings of 
this survey provide us with a better understanding of the specific types of HEOR 
evidence payers are interested in for pharmaceutical products entering the market. 
This nuanced understanding of payer preferences may allow for greater alignment 
between payer organizations and pharmaceutical companies, and will assist phar-
maceutical companies in planning future investments.
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OBJECTIVES: The Californian Technology Assessment Forum (CTAF) publishes 
reports that make recommendations on the comparative clinical effectiveness and 
value of medical interventions. The recommendations of CTAF, which is managed 
by the Institute for Clinical and Economic Review and funded by Blue Shield of 
California, are not binding and they do not determine health plan benefit coverage. 
In April 2014, CTAF gained a degree of public attention when they recommended 
that the Hepatitis C virus (HCV) treatments OLYSIO and SOVALDI be only used 
immediately in patients with advanced liver disease or those awaiting transplants 
based on a report including cost-utility economic modelling. This research aimed 
to systematically analyse all CTAF reports to determine what types of health 
technologies they assess, how restrictive their recommendations are, and how 
this has evolved over time. METHODS: All publically available CTAF reports were 
extracted and their date, indication, technology type, and recommendation were 
extracted. RESULTS: CTAF have issued 119 medical technologies appraisals since 
October 2002. 26/119 (22%) were recommended, 18/119 (15%) received restricted 
recommendations, and 75/119 (63%) not recommended. 33/119 appraisals (28%) 
were for diagnostic tests, 28/119 devices (24%), 27/119 (23%) surgery, 25/117 (21%) 
radio/radiation/laser-based emission therapies, 3/117 (3%) other, and only 3/117 
(3%) branded drugs. The branded drug submissions were for Avastin in metastatic 
OBJECTIVES: Biologic agents represent significant medical advances for rheumatoid 
arthritis (RA), and multiple sclerosis (MS). Yet, specialty tiers under the initial cover-
age limit (ICL) period of Medicare Part D require a coinsurance of up to 33% for such 
drugs. This study is the first to examine the impact of cost-sharing increases faced 
with specialty tiers on adherence and discontinuation among Medicare patients 
using RA and MS biologics. METHODS: This quasi-experimental study examined 
changes in outcomes across the Part D catastrophic coverage period in the previous 
year (pre-period) and the ICL period in the current year (post-period) for patients 
not receiving low-income subsidies (non-LIS) who faced coinsurance levels of 5% in 
the pre-period and 25%-33% in the post-period compared to a control group of LIS 
patients who faced the same cost-sharing ($5 copay) in the pre- and post-periods. 
Using the 2006-2010 5% Medicare files we identified patients with MS (ICD-9-CM 340.
xx) and RA (ICD-9-CM 714.xx) with continuous fee-for-service and Part D coverage 
and use of Part D biologics indicated for MS (N= 1887) and RA (N= 1982), respec-
tively, during the pre-period. Outcomes included adherence (proportion of days 
covered> = 0.8) and discontinuation (continuous 30-day gap) for Part D-covered, Part 
B-covered, and all biologics. GEE logit regressions adjusting for patient demograph-
ics and clinical severity and Part D plan formulary characteristics were estimated. 
Patient-level fixed-effects models were used in sensitivity analyses. RESULTS: 
The substantial increase in cost sharing under specialty tiers was associated with 
lower adherence (MS:OR= 0.56,p< 0.001; RA:OR= 0.50,p< 0.001) and higher likelihood 
of having gaps in Part D biologic (MS:OR= 1.56,p< 0.001; RA:OR= 2.73,p< 0.001) among 
non-LIS compared to LIS patients. Overall biologic use also declined due to limited 
substitution with Part B biologics in non-LIS patients. Sensitivity analyses showed 
consistent findings. CONCLUSIONS: The increased cost sharing under specialty 
tiers was associated with a decline in adherence and increase in discontinuation 
of MS and RA biologics.
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OBJECTIVES: A key portion of the Affordable Care Act’s new coverage, particu-
larly for chronic disease, is the prescription drug benefit. Each plan’s generos-
ity will depend on the particular mix of drugs for a given patient, not just the 
benefit structure. For a market basket of drugs, we assess the generosity of drug 
coverage for the four metal tiers in the Federally Facilitated health insurance 
exchanges. METHODS: We examined the 27 federally facilitated exchanges and 
7 partnership exchanges, for which characteristics of all plans on the exchanges 
were publicly available from data.gov for 2014. These files, however, do not contain 
drug formulary data, so we also use a unique data source of drug formulary data, 
from Managed Markets Insight & Technology. We were able to identify a total 
of 2,826 unique plan-formulary combinations with formulary and price data for 
21 drugs in these therapeutic areas. For each drug, we collected the price for a 
standard prescription fill from drugs.com, which allowed us to convert coinsur-
ance rates into prices. We then created a generosity index as the ratio of the 
out-of-pocket payment to the price of the drug. RESULTS: For individuals with 
higher out-of-pocket spending, there is considerable variation in the generosity 
of prescription drug coverage in all metal tiers. Comparisons by plan type indicate 
that PPO plans provide more generous prescription drug coverage, except in the 
bronze tier, for which HMO plans are significantly more generous than PPO plans 
until individuals have spent $5,000, or more, out of pocket. CONCLUSIONS: Given 
the substantial variation in generosity of drug coverage, consumers may have 
trouble finding the plan that best balances their ability to pay premiums, toler-
ance for financial risk, and preferences between prescription drug and all other 
costs.
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OBJECTIVES: A “biosimilar” is a biological medicine similar to a licensed biologi-
cal medicine (“originator”). As of October 2014, six biosimilars are licensed and 
marketed in Great Britain (GB) (three biosimilar filgrastims, two biosimilar epo-
etins and one biosimilar somatropin). Biological medicines are highly costly to 
the NHS, so it is expected that biosimilars will have an increasing presence as a 
cost-saving mechanism. This study explored the uptake of biosimilars within GB 
formularies. METHODS: Websites of acute trusts in England and health boards in 
Scotland and Wales were searched for the most recent drug formularies. The pres-
ence of biosimilars in a formulary was examined for all six products. Formularies 
that listed at least one biosimilar were considered to have a positive recognition 
of these products. RESULTS: Of 158 acute trusts in England and 21 health boards 
in Scotland and Wales, 176 websites were available, providing 144 formularies 
(England: 127, Scotland: 9; Wales: 7; England/Scotland shared: 1). 17 formular-
ies were shared across trusts and boards. At least one biosimilar was listed in 
63 formularies. While 45 formularies listed at least one biosimilar filgrastim, 31 
and 17 formularies listed biosimilar somatropin and epoetin, respectively. Five 
formularies listed at least one biosimilar from each of the three classes, 20 for-
mularies listed at least one from two classes, and 38 formularies listed at least 
one from only one class. In 19 formularies, at least one biosimilar was listed in 
preference to an originator product as first line therapy (filgrastim: 16; somatro-
pin: 5; epoetin: 1). CONCLUSIONS: The results of this survey suggest that 44% of 
formularies in Great Britain list at least one biosimilar, and in 30% of these, these 
are listed in preference to the originator product. This appears to be a low level 
of penetration into formularies given that these biosimilars have been available 
for over five years.
